2016 Press Releases

Keyword Search
 
2017 | 2016
DateTitle 
11/14/16Pulse Biosciences Quarterly Nano-Pulse Stimulation (NPS) Update
Investor conference call today at 1:30 p.m. PST / 4:30 p.m. EST BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 14, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on new developments and significant advancements for its novel NPS platform in key markets. T... 
Printer Friendly Version
11/14/16Pulse Biosciences Announces First Clinical Use of the Proprietary PulseTx Platform in a Pilot Study in Dermatology
PulseTx System Enters Clinic in First of Multiple Potential Applications BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 14, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced the treatment of the first patient using the company’s proprietary and first-of-its-kind PulseTx System in a pilot study in dermatolog... 
Printer Friendly Version
11/11/16Pulse Biosciences Announces New Data That Reinforce Potential Immuno-Oncology Benefits of Nano-Pulse Stimulation Technology
Data from Three Preclinical Studies Demonstrate NPS Triggers Immunogenic Cell Death, Stimulates Anti-tumor Immune Responses and Inhibits Metastases BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 11, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced the results of three preclinical studies that further valid... 
Printer Friendly Version
11/02/16Pulse Biosciences to Host Third Quarter Investor Conference Call on November 14, 2016
BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 2, 2016-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its third quarter investor conference call on Monday, November 14, 2016, at 4:30 p.m. EST / 1:30 p.m. PST. The company will highlight progress to date on corporate strategies and upcoming milestones, as well as provide an upda... 
Printer Friendly Version
10/18/16Pulse Biosciences to Present New Data at the Society for Immunotherapy in Cancer Annual Meeting
Data to Showcase Application of Novel Nano-Pulse Stimulation Technology in Immuno-Oncology BURLINGAME, Calif.--(BUSINESS WIRE)--Oct. 18, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced that it has three posters accepted for presentation at the upcoming Society for Immunotherapy in Cancer (SITC) Annua... 
Printer Friendly Version
09/07/16Pulse Biosciences Provides Overview of Corporate Strategy and Updates on Clinical Development for Novel PulseTx Platform
Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif.--(BUSINESS WIRE)--Sep. 7, 2016-- Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today provides a financial and corporate strategy update. “We are very encouraged by the progress we have made in a short period of time,” said Darrin ... 
Printer Friendly Version
08/30/16Pulse Biosciences Appoints Holly Hartman as Vice President of Business Development and Corporate Strategy
BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 30, 2016-- Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Holly Hartman, Ph.D., J.D., as its Vice President, Business Development and Corporate Strategy. Dr. Hartman joins Pulse Biosciences after more than eight years in business developm... 
Printer Friendly Version
08/24/16Pulse Biosciences Appoints Edward Ebbers as Vice President and General Manager of Dermatology Products
– With more than 35 years of leadership experience, Ebbers to oversee development of Nano-Pulse Electro-Signaling technology for application in dermatologic conditions – BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 24, 2016-- Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Edward Ebbers, an expe... 
Printer Friendly Version
08/10/16Pulse Biosciences to Host September Investor Conference Call to Highlight Corporate Progress, Strategic Focus and Future Milestones
BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 10, 2016-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Electro-Signaling (NPES™), announced today it will host an investor conference call on September 7, 2016, at 4:30 p.m. EDT / 1:30 p.m. PDT. The company will highlight progress to date and provide an overview of corporate strategies, financials, and futur... 
Printer Friendly Version
06/21/16Pulse Biosciences Announces Closing of Initial Public Offering Over-allotment
BURLINGAME, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its underwriters’ over-allotment for 749,846 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of approximately $3.0 million before customary underwriting discounts and offering-related expenses. Through the closing of its initial public offering on May 22, 2016 and the over-allotment shares issued today, Pulse has issued an aggregate of... 
Printer Friendly Version
05/23/16Pulse Biosciences Announces Closing of Initial Public Offering
BURLINGAME, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its initial public offering of 5,000,000 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of $20 million before customary underwriting discounts and offering-related expenses.  Pulse Biosciences granted the underwriters a 45-day over-allotment option to purchase up to an additional 750,000 shares at the initial public offering price.  Al... 
Printer Friendly Version
05/17/16Pulse Biosciences Announces Pricing of Initial Public Offering
BURLINGAME, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $4.00 per share. All of the 5,000,000 shares are being offered by Pulse Biosciences.  In addition, Pulse Biosciences granted the underwriters a 45-day over-allotment option to purchase up to an additional 750,000 shares at the initial public offering price. The shares are expected to begin tra... 
Printer Friendly Version